Page last updated: 2024-10-30

leflunomide and Vertigo

leflunomide has been researched along with Vertigo in 1 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Vertigo: An illusion of movement, either of the external world revolving around the individual or of the individual revolving in space. Vertigo may be associated with disorders of the inner ear (EAR, INNER); VESTIBULAR NERVE; BRAINSTEM; or CEREBRAL CORTEX. Lesions in the TEMPORAL LOBE and PARIETAL LOBE may be associated with FOCAL SEIZURES that may feature vertigo as an ictal manifestation. (From Adams et al., Principles of Neurology, 6th ed, pp300-1)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rahman, MU1
Poe, DS1
Choi, HK1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Pilot Trial of Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss[NCT02828033]Early Phase 110 participants (Anticipated)Interventional2017-02-01Recruiting
Clinical Trial of Etanercept (TNF-α Blocker) for Treatment of Blast-Induced Tinnitus[NCT04066348]Phase 2310 participants (Anticipated)Interventional2022-07-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

1 other study available for leflunomide and Vertigo

ArticleYear
Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study.
    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2001, Volume: 22, Issue:5

    Topics: Adult; Aged; Antirheumatic Agents; Cochlear Diseases; Etanercept; Female; Follow-Up Studies; Hearing

2001
Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study.
    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2001, Volume: 22, Issue:5

    Topics: Adult; Aged; Antirheumatic Agents; Cochlear Diseases; Etanercept; Female; Follow-Up Studies; Hearing

2001
Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study.
    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2001, Volume: 22, Issue:5

    Topics: Adult; Aged; Antirheumatic Agents; Cochlear Diseases; Etanercept; Female; Follow-Up Studies; Hearing

2001
Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study.
    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2001, Volume: 22, Issue:5

    Topics: Adult; Aged; Antirheumatic Agents; Cochlear Diseases; Etanercept; Female; Follow-Up Studies; Hearing

2001